FGFR2 and neoplasm: The concomitant blockade of VEGF signaling with the VEGFR2-blocking monoclonal antibody and FGF signaling by adenovirus-delivered soluble form of FGFR2 (FGF-trap) significantly reduced tumor burden and vessel density compared to the anti-VEGFR2 alone [69].